Federica Blua

Via P. Giuria 9
Turin, 10125, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic Acid Scaffold to Generate COXTRANs: A New Class of Dual Cyclooxygenase Inhibitors-Thromboxane Receptor Antagonists.

Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic Acid Scaffold to Generate COXTRANs: A New Class of Dual Cyclooxygenase Inhibitors-Thromboxane Receptor Antagonists.

Journal: Journal of medicinal chemistry

Published: October 22, 2025

Solid Lipid Nanoparticles by Coacervation from Natural Soaps: Preliminary Studies for Oral Delivery of an Insulin Analogue.

Solid Lipid Nanoparticles by Coacervation from Natural Soaps: Preliminary Studies for Oral Delivery of an Insulin Analogue.

Journal: Pharmaceutics

Published: August 18, 2025

NLRP3 inhibition protects human coronary endothelial cells from oxidative and lipotoxic stress.

NLRP3 inhibition protects human coronary endothelial cells from oxidative and lipotoxic stress.

Journal: Biochemical pharmacology

Published: August 04, 2025

Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150.

Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150.

Journal: Vascular pharmacology

Published: November 27, 2024

Exploring flavylium-based SWIR emitters: Design, synthesis and optical characterization of dyes derivatized with polar moieties.

Exploring flavylium-based SWIR emitters: Design, synthesis and optical characterization of dyes derivatized with polar moieties.

Journal: Bioorganic chemistry

Published: March 18, 2024

Novel NLRP3 inhibitor INF195: Low doses provide effective protection against myocardial ischemia/reperfusion injury.

Novel NLRP3 inhibitor INF195: Low doses provide effective protection against myocardial ischemia/reperfusion injury.

Journal: Vascular pharmacology

Published: February 19, 2024

Discovery of a septin-4 covalent binder with antimetastatic activity in a mouse model of melanoma.

Discovery of a septin-4 covalent binder with antimetastatic activity in a mouse model of melanoma.

Journal: Bioorganic chemistry

Published: December 06, 2023

Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation.

Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation.

Journal: European journal of medicinal chemistry

Published: May 04, 2023

Comparative Study of Different H2S Donors as Vasodilators and Attenuators of Superoxide-Induced Endothelial Damage.

Comparative Study of Different H2S Donors as Vasodilators and Attenuators of Superoxide-Induced Endothelial Damage.

Journal: Antioxidants (Basel, Switzerland)

Published: January 18, 2023

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein.

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein.

Journal: Molecules (Basel, Switzerland)

Published: November 14, 2022

Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Journal: Molecules (Basel, Switzerland)

Published: June 14, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026